Status:
UNKNOWN
Arthroscopic Synovectomy Combined With DMARDs in the Treatment of Refractory Elbow Rheumatoid Arthritis
Lead Sponsor:
Peking University Third Hospital
Conditions:
Rheumatoid Arthritis of Ankle
Eligibility:
All Genders
18-60 years
Brief Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic and aggressive polyarthritis. The prevalence of RA in China is about 0.42%. Arthroscopic synovectomy (AS) is an important me...
Eligibility Criteria
Inclusion
- The patients who fulfilled the 1987 ACR（American College of Rheumatology) or 2010 ACR/EULAR（European League Against Rheumatism） RA classification criteria.
- The age is more than 18 years old and less than 60 years old.
- They received stable traditional DMARDs (including Chrysopidae, leflunomide, sulfasalazine, hydroxychloroquine, eilamod) or biological dmrads (including tumor necrosis factor antagonists, IL(Interleukin)-6 receptor antagonists, CD20 monoclonal antibodies) for at least 6 months.
- The disease is still in the active stage, which means the disease activity score (DAS28) is more than 3.2, and the elbow joint function is obviously limited.
- The patient agreed to undergo arthroscopic synovectomy.
- No contraindications were found.
Exclusion
- The disease is in remission.
- The patient has contraindications.
- Arthroscopic synovectomy was performed in different patients.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04454034
Start Date
August 1 2019
End Date
December 31 2021
Last Update
June 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Univerisity Third Hospital
Beijing, Beijing Municipality, China, 100191